Treatment of vaginal trichomoniasis with a new anti-protozoal compound ( -chloromethyl-2-methyl-5-nitro-1-imidazole-ethanol).
D000433:1-Propanol / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001773:Blood Cells / Q000032:analysis; D004748:Entamoeba histolytica / Q000187:drug effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009574:Nitro Compounds / Q000494:pharmacology / Q000627:therapeutic use; D014247:Trichomonas Vaginitis / Q000188:drug therapy*; D014246:Trichomonas vaginalis / Q000187:drug effects
D000981:Antiprotozoal Agents; D007093:Imidazoles; D009574:Nitro Compounds; D008795:Metronidazole; D000433:1-Propanol